Fig. 1: Findings of progressive bone disease over time in newly diagnosed multiple myeloma.

a Overview of findings of progressive bone disease (PBD) ”PBD clinician-initiated imaging” shows cases found due to imaging performed on clinical suspicion of progressive bone disease and cases with biochemical progression or CRAB, ”PBD: preplanned imaging” are cases of progressive bone disease found due to preplanned imaging. 70.3 % of all PBD cases in our study were found by preplanned imaging investigation with whole body low dose-CT. Preplanned imaging investigations were performed at months 12 (n = 89), 24 (n = 79), 30 (n = 181), 36 (n = 164) 42 (n = 126) and 48 (n = 93). b Description of findings since last imaging, earlier treatments, type and placement of lesions and results of last treatments for the cases of progressive bone disease seen in a. ”New osteolysis” was defined as a new osteolytic lesion of at least 10 mm and “increase of existing lesion” was defined as increase in size of existing osteolytic lesion of at least 25% and at least 10 mm. * Reimbursement for maintenance with lenalidomide was not approved until autumn 2019. **One patient was reevaluated with MR in which lesions were less than on WBLDCT. *** The 5 cases where treatment was not initiated in the found by clinician group was due to already being. in active treatment, which was deemed effective. **** Three cases in PBD found by preplanned imaging had spontaneous fracture only (month 12), One case in the PBD found by clinician initiated imaging (month 26).